Trial Profile
A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subject
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Paricalcitol (Primary)
- Indications Renal failure
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 03 Apr 2018 Status changed from recruiting to completed.
- 03 Apr 2018 New trial record
- 03 Jan 2013 Abbvie added as an association based on information about Abbott's restructure, as reported in an Abbvie media release.